Study of NMDA Antagonists and Neuropathic Pain

Summary

The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity.

In clinical, after ketamine cure, clinicians have often difficulties to treat patients in order to maintain analgesia or suggest another treatment if analgesia induced by ketamine was not effective, which occurs in one quarter of patients. It will be very useful for monitoring of painful patients evaluate if memantine or dextromethorphan could be an effective therapeutic alternative in neuropathic pain treatment.

Conditions

• Neuropathic Pain

Interventions

DRUG

Dextromethorphan (drug used like antitussive)

The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity

DRUG

Memantine (drug used in Alzheimer's disease)

The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity

DRUG

Placebo (lactose)

The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity

Sponsors & Collaborators

• Dr Malou Navez, Pain Clinic, Saint-Etienne Hopital

  collaborator UNKNOWN

• Dr Marc Sorel, Pain Clinic, Nemours Hospital

  collaborator UNKNOWN

• Dr Anne-Margot Duclot, Pain Clinic, Paris Rotschild Hospital

  collaborator UNKNOWN

• Dr Monique Belon, Pain Clinic, Aurillac Hospital

  collaborator UNKNOWN

• Dr Marie-Christine Crosmary/Dr Renato Colamarino, Pain Clinic, Vichy Hospital

  collaborator UNKNOWN

• Dr Mohamed El Ayadi, Pain Clinic, Issoire Hospital

  collaborator UNKNOWN

• Dr Géraldine Brumauld de Montgazon, Pain Clinic, La Rochelle Hospital

  collaborator UNKNOWN

• University Hospital, Clermont-Ferrand

  lead OTHER

Principal Investigators

• Gisèle PICKERING · University Hospital, Clermont-Ferrand

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2012-05-31

Primary Completion

2014-06-30

Completion

2016-09-07

Countries

• France

Study Locations